Calcitonin gene-related peptide (CGRP) receptor is a complex molecule that consists of calcitonin receptorlike receptor and receptor activity-modifying protein-1 (RAMP1). It was recently reported that RAMP1-deficient mice (RAMP1(À/À)) showed inflammatory responses with a transiently significant increase in serum CGRP levels and proinflammatory cytokines when compared with RAMP1( þ / þ ) mice. The aim of this study was to investigate the relationship between the human RAMP1 gene and cerebral infarction (CI) using singlenucleotide polymorphisms (SNPs) in a Japanese population. We selected six SNPs in the human RAMP1 gene (rs3754701, rs3769048, rs7557078, rs1584243, rs10199956 and rs7590387) and performed a casecontrol study using each SNP and haplotype in 171 CI patients and 234 controls. There were no significant differences in overall distribution of genotype and allele frequencies of the SNPs between the CI and control groups. However, there was a significant difference in overall distribution between the CI and control groups (Po0.001) in the haplotype-based case-control study with the combinations of rs3754701-rs3769048-rs7590387. The T-A-C susceptibility haplotype for CI was significantly more frequent than in the control group (P ¼ 0.0024). The results suggest that the T-A-C haplotype is a genetic marker for CI, and that RAMP1 or neighbouring genes are associated with increased susceptibility to CI.
Introduction
Cerebral infarction (CI) is thought to be a heterogeneous multifactorial disease associated with several environmental factors and genetic variants. Factors such as high blood pressure, cigarette smoking, diabetes mellitus, arterial diseases and atrial fibrillation can lead to the development of CI. Identification of susceptibility genes for CI might enhance the prediction of risk for the disease. In addition, it has been reported that inflammatory reactions are associated with CI, particularly as interleukin-1, interleukin-6, tumour necrosis factor-a, transforming growth factor-b, interleukin-10, interferon-g and granulocyte-colony-stimulating factor are produced in the acute phase of CI. [1] [2] [3] Calcitonin gene-related peptide (CGRP) is a neuroimmune modulator related to cardiovascular regulation. 4 CGRP signalling is expressed through the CGRP receptor, which is composed of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein-1 (RAMP1). 5 Furthermore, aCGRP is known to have the most potent pharmacological vasodilatory activity. 6 Tsujikawa et al. reported that RAMP1-deficient mice (RAMP1(À/À)) showed increased inflammatory responses and high serum levels of proinflammatory cytokines when compared with RAMP1( þ / þ ) mice. In addition, aCGRP and bCGRP appear to equally suppress the production of tumour necrosis factor-a and interleukin-12 in bone marrow-derived dendritic cells stimulated with lipopolysaccharide. 7 Um et al. reported that the expression of IL-1 in the brain was increased during the early and chronic stage of CI. 8 The aim of this study was to investigate the relationship between CI and human RAMP 1 gene using single-nucleotide polymorphisms (SNPs) and haplotypes in a Japanese population.
Materials and methods

Subjects
Subjects diagnosed with CI were recruited at Nihon University Itabashi Hospital and other neighbouring hospitals in Tokyo between 1993 and 2003. This study included a group of 171 patients who were diagnosed with CI. Control subjects were selected from among the outpatients at our hospital during the same period. The study group consisted of 171 patients (101 men and 70 women; mean age 65.8 ± 13.1 years) diagnosed with CI by computed tomography or magnetic resonance imaging. All patients had neurological deficits that persisted for 41 month. A total of 234 subjects without CI (113 men and 121 women; mean age 77.7 ± 4.1 years) were used as control subjects. Control subjects had vascular risk factors, such as hypertension and hypercholesterolaemia, but no cerebrovascular disease. Diagnosis of diabetes mellitus was based on the World Health Organization (WHO) criteria. Hypercholesterolaemia was defined as plasma total cholesterol 4220 mg per 100 ml, or current use of a lipid-lowering drug in addition to a confirmed diagnosis of hypercholesterolaemia. Smokers were defined as current or former smokers, whereas nonsmokers were defined as subjects with no history of previous or current smoking. History of smoking was recorded and current smokers included individuals who had stopped smoking o1 year before enrolment. Daily alcohol intake was assessed by interview. The frequency of drinking during a typical week and the alcohol intake on each occasion were determined and used to calculate the alcohol intake per week, which was then divided by 7 to obtain the mean alcohol intake per day. Subjects were asked to estimate their alcohol intake on the basis of gou (180 ml), which is a traditional Japanese drinking unit; 1 gou of Japanese Sake contains 20 g of ethanol, while a similar amount (180 ml) of Japanese Shochu contains 50 g of ethanol, a standard bottle of beer (550 ml) contains 22 g of ethanol, 2 single whiskeys (60 ml) contain 20 g of ethanol and 120 ml of wine contains 12 g of ethanol. Both groups were recruited from the northern area of Tokyo, and informed consent was obtained from each individual, as per the protocol approved by the Human Studies Committee of Nihon University. 9 
Genotyping
On the basis of the allelic frequency data for the registered SNPs from the National Center for Biotechnology Information (NCBI) website and from the Applied Biosystems Inc. (Foster City, CA, USA) -Celera Discovery System, we selected SNPs with minor allele frequencies of 20% or greater. This criterion was selected because SNPs with a high minor allele frequency are very useful as genetic markers in genetic association studies. We thus selected six SNPs in the human RAMP1 gene as markers for the genetic association experiment.
The minor allele frequencies for each SNP among the Japanese subjects were 410% (screening estimate from the Celera Company), which indicates that they should all be effective genetic markers. All SNPs were confirmed using the dbSNP on the NCBI website and the Applied Biosystems-Celera Discovery System. Accession numbers were as follows: rs3754701 (C_27496443_10); rs3769048 (C_9091474_10); rs7557078 (C_2149706_10); rs1584243(C_2149746_10); rs10199956 (C_30171509_10); and rs7590387 (C_26481962_10). All SNPs were located in introns ( Figure 1 ). Blood samples were collected from all participants, and genomic DNA was extracted from peripheral blood leukocytes by phenol and chloroform extraction. 10 Genotyping was performed using the TaqMan SNP Genotyping Assay (Applied Biosystems). TaqMan SNP Genotyping Assays were performed using the method for Taq amplification.
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On the 5 0 -nuclease assay, discrimination occurs during PCR due to allele-specific fluorogenic probes that, when hybridized to the template, are cleaved by the 5 0 -nuclease activity of Taq polymerase. The probes contain a 3 0 -minor groove-binding group that Haplotype of RAMP1 gene and hypertension T Nakazato et al hybridizes to single-stranded targets with greater sequence specificity than ordinary DNA probes. This reduces nonspecific probe hybridization, and results in low background fluorescence on 5 0 -nuclease PCR assay (TaqMan, Applied Biosystems). Cleavage results in increased emission of reporter dye. Each 5 0 -nuclease assay requires two unlabelled PCR primers and two allele-specific probes. Each probe is labelled with two reporter dyes at the 5 0 -end. In this study, VIC and FAM were used as reporter dyes. Primers and probes used in TaqMan SNP Genotyping Assays (Applied Biosystems) were selected on the basis of the information available at the Applied Biosystems website (http://myscience. appliedbiosystems.com).
PCR amplification was performed using 6 ml of TaqMan Universal Master mixand No AmpErase UNG (2 Â ) (Applied Biosystems) in a 12-ml final reaction volume containing 2 ng of DNA, 0.22 ml of TaqMan SNP Genotyping Assay mix (20 Â or 40 Â ), primers at a concentration of 900 nmol l À1 each, and probes at a final concentration of 200 nmol l À1 each. Thermal cycling conditions were as follows: 50 1C for 2 min; 95 1C for 10 min; 40 cycles of 95 1C for 15 s; and 62 1C for 1 min. Thermal cycling was performed using the GeneAmp 9700 system (Applied Biosystems Inc.). Each 96-well plate contained 80 DNA samples of an unknown genotype and four reaction mixtures containing reagents but no DNA (control). Control samples without DNA are a necessary part of Sequence Detection System (SDS) 7700 signal processing, as outlined in the TaqMan Allelic Discrimination Guide (Applied Biosystems). Plates were read on the SDS 7700 instrument with the end point analysis mode of the SDS version 1.6.3 software package (Applied Biosystems). Genotypes were determined visually on the basis of the dye-component fluorescent emission data depicted in the X-Y scatter-plot of the SDS software. Genotypes were also determined automatically by the signal processing algorithms of the software. The results for each scoring method were saved in two separate output files for later comparison. 12 We performed haplotype analysis on five SNPs. On the basis of the genotype data of the four genetic variations, the frequency of each haplotype was estimated using the expectation/maximization algorithm. 13 For linkage disequilibrium analysis and haplotype-based case-control study, SNPAlyze version 3.2 was used (Dynacom Co. Ltd, Yokohama, Japan), which is available at http://www.dynacom. co.jp/products/package/snpalyze/index.html.
Statistical analysis
Data are shown as means±s.d. Differences between the CI and control groups were assessed by analysis of variance, followed by Fisher's protected least significant difference test. Hardy-Weinberg equilibrium was assessed by w 2 -analysis. When the sizes of the expected values were small (o2.0), genotypes were combined. 14 The overall distribution of the SNP alleles was analyzed by 2 Â 2 contingency tables, and the distribution of the SNP genotypes between the CI patients and controls was tested using a two-sided Fisher's exact test and multiple logistic regression analysis. Statistical significance was established at Po0.05. The threshold value of the frequencies of the haplotypes included in the analysis was set to 1/2n (n is the numbers of subjects in each group), as suggested by Excoffier and Slatkin. 15 All haplotypes below the threshold value were excluded from analysis. Overall distribution of haplotypes was analyzed using 2 Â m contingency tables with a value of Po0.05 considered to indicate statistical significance. The P-value significance of each haplotype was determined by w 2 -analysis and the permutation method using the software SNPAlyze version 3.2.
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Results
The clinical features for CI patients and the control group are shown in Table 1 . Systolic blood pressure and diastolic blood pressure, age, pulse rate, serum concentrations of creatinine and frequencies of smoking, drinking and diabetes mellitus were significantly higher in the CI group, as compared with the control group. Body mass index did not significantly differ between the two groups.
The distribution of genotypes and alleles of the six SNPs is shown in Table 2 . Because the genotype distribution of SNP5 in the controls was significantly different from the Hardy-Weinberg equilibrium values (P ¼ 0.0007), we excluded SNP5 from the statistical analysis. Thus, there were no significant differences in overall distributions of frequencies in genotypes and alleles for any of the six SNPs between the CI and control groups.
On linkage disequilibrium analysis, we omitted SNP5 because its genotype distribution in the control group showed significant differences from the Hardy-Weinberg equilibrium values. As most values for |D 0 | between each pair of SNPs were beyond 0.5, all five SNPs are located in one haplotype block (data not shown), and because the r 2 values of all combinations were below 0.5 ( Figure 2 ), all five SNPs were suitable for conducting a haplotype-based case-control study. Among the 23 combinations of SNPs, seven showed significant differences in the overall study. Of the 21 combinations, we show the top five haplotypes with the smallest P-values in Table 3 . The frequency of the A-C-G haplotype (established by SNP2-SNP3-SNP6: P ¼ 0.029), the frequency of the A-C-C-G haplotype (established by SNP2-SNP3-SNP4-SNP6: 0.047) and the frequency of the A-C-G haplotype (established by SNP2-SNP4-SNP6: 0.047) were significantly lower for CI patients than for control subjects. The frequencies of the A-C-C Haplotype of RAMP1 gene and hypertension T Nakazato et al haplotype (established by SNP2-SNP3-SNP6: 0.048) and the T-A-C haplotype (established by SNP1-SNP2-SNP6: 0.0024) were significantly higher for CI patients than for control subjects
Discussion
Receptor activity-modifying protein-1 is involved in the vascular endothelium and mouse bone marrow macrophages. 16, 17 The human RAMP-1 gene is located on chromosome 2, at 2p36-2q37.1, spanning approximately 60 kb and containing 3 exons. RAMP1 protein has 148 amino acids with a 26-amino-acid N-terminal signal peptide, an extracellular domain of approximately 90 amino acids, a single transmembrane domain of 20 amino acids and a C-terminal tail of 10 amino acids. RAMPs are required to transport CRLR to the plasma membrane. CRLR, a receptor with seven transmembrane domains, can function as either a CGRP receptor or an adrenomedullin receptor, depending on which members of the RAMP family are expressed. The specificity of the CGRP receptor appears to be Haplotypes with frequency 0% were estimated using SNPAlyze software. P-value was calculated by w 2 -analysis. *Po0.01.
